FMP

FMP

Enter

ARVN - Arvinas, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/ARVN.png

Arvinas, Inc.

ARVN

NASDAQ

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

19.08 USD

0.35 (1.83%)

Historical Prices

From:

To:

We are unable to load the chart at this time.

fmp-logo

About

ceo

Dr. John G. Houston Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatmen...

CIK

0001655759

ISIN

US04335A1051

CUSIP

04335A105

Address

5 Science Park

Phone

203 535 1456

Country

US

Employee

445

IPO Date

Sep 27, 2018

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

ARVN Financial Summary

CIK

0001655759

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

04335A105

ISIN

US04335A1051

Country

US

Price

19.08

Beta

1.97

Volume Avg.

736.02k

Market Cap

1.31B

Shares

-

52-Week

17.37-53.08

DCF

-17.43

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-3.98

P/B

-

Website

https://www.arvinas.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest ARVN News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep